American Heart Journal
Volume 157, Issue 5 , Page e29 , May 2009

Response to “Atrial fibrillation and atherothrombosis: The importance of anticoagulation” by Escobar C and Barrios V

  • on Behalf of the REACH Registry Investigators

References 

  1. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855–863.e2
  2. Goto S. Cardiovascular risk factors in patients at high risk of atherothrombosis: what can be learned from registries?. Thromb Haemost. 2008;100:611–613
  3. Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke. 2008;39:1740–1745
  4. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–2696
  5. Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008;134:559–567

PII: S0002-8703(09)00158-6

doi: 10.1016/j.ahj.2009.03.003

American Heart Journal
Volume 157, Issue 5 , Page e29 , May 2009

Article Tools